Professor Anne Keogh, MBBS MD FRACPLaboratory Head, Cardiac Physiology and Transplantation DivisionProfessor of Medicine, University of New South Wales
|
 |
Research Focus:
Our research programs focus on pulmonary arterial hypertension, heart transplantation, immunosuppression and heart failure.
We aim to determine the best tailored therapy for individual patients with Class I-IV heart failure, including drug therapy, synchronised pacing and ventricular assist devices.
For Pulmonary Hypertension, we are working with the broadest range of drugs available in Australia. Available agents include drugs for patients who fail to respond to Bosentan or who are not eligible. These include Sitaxsentan, Ambrisentan, Sildenafil, Prostacyclin, Iloprost and Treprostinil.
In place now is a comprehensive management system for dealing with pulmonary hypertension from any cause. Pulmonary thromboendarterectomy has been performed successfully for eighteen months.
Post transplant immunosuppressive trials include Sirolimus for Cyclosporine nephrotoxicity and transplant vasculopathy, and Everolimus post heart transplant.
Summary of Current Trials
Sirolimus: A study of the safety of long term administration of Sirolimus where renal impairment has occurred after heart transplantation.
Everolimus: A multicentre, randomized study using Everolimus in heart transplant recipients.
AMB 220 E: An open-label, long term study of Ambrisentan in Pulmonary Hypertension subjects having completed Myogen study AMD-220.
ARIES 3: A phase 3, long term, open label, multicentre safety and efficacy study of Ambrisentan in subjects with Pulmonary Hypertension.
A 16 week, international, multicentre, double-blind, randomized, placebo-controlled comparison of the efficacy and safety of Oral UT-15C sustained release tablets in combination with an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor in subjects with Pulmonary Arterial Hypertension.
An open label extension of UT-15C SR in subjects with Pulmonary Arterial Hypertension.
Sitaxsentan: A Phase III, randomised, double-blind, placebo-controlled safety and efficacy study of Sitaxsentan with an open label Bosentan arm in patients with Pulmonary Arterial Hypertension.
The primary objective is to evaluate the safety and efficacy of Sitaxsentan sodium as compared to placebo in Primary Pulmonary Hypertension with secondary endpoint evaluation of the pharmacokinetics of Sitaxsentan.
Sildenafil on top of Bosetan Clinical Trial: A multi national, multicentre, randomized, double blind study to assess the efficacy and safety of oral Sildenafil 20mg tds when added to Bosentan in the treatment of subjects aged 18 years and above, with Pulmonary Arterial Hypertension (PAH).
Pfizer Study: use of bosentan on top of sildenafil - acombination study in PAH
COMPASS II: use of sildenafil on top of bosentan - a combination study in PAH
Co-Investigators:
Eugene Kotlyar, MBBS MD
Karen Brown, CNS
Carolyn Corrigan, CNS
Annette Pidoux, RN
Carmen Herrera, RN
Ross Pettersson (Database Manager)
Collaborators:
Fatemah Aghlaghi; Rhode Island NY
John Ray; Clinical Pharmacology, St Vincent's Hospital
Kotlyar E, Sy R, Keogh A, Kermeen F, Macdonald P, Hayward C, McNeil K, Celermajer D. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital cardiac disease. Cardiol Young 2006; 16:268-274.
Kobashigawa J, Renlund D, Gerosa G, Almenar L, Eisen H, Keogh A, Lehmkuhl H, Livi H, Ross H, Segovia J, Yonan N. Similar efficacy and safety of enteric-coated mycophenolate mofetil in de novo heart transplant recipients: results of a 12 month single-blind, randomised parallel-group multicenter study. J Heart Lung Transplant 2006; 25:935-941.
Wlodarczyk J, Cleland L, Keogh A, McNeil K, Perl K, Weintraub R, Williams T. Public funding of bosentan for the treatment of pulmonary artery hypertension in Australia - cost effectiveness and risk sharing. Pharmacoeconomics 2006; 24:903-915.
Keogh A. Guest Editorial. Transplantation 2006; 82: in press.
Langleben D, Naije R, Frost A, Keogh A, Lawrence C, Badesch D, Shahlai N, Mather J, Barst R, Shapiro S, Galie N. Treatment of pulmonary hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Amer Coll Cardiol 2006; 47:2049-2056.
Keogh A, Mc Neil K, Wlodarczyk J, Gabbay E, Wiiliams T. Quality of life in pulmonary arterial hypertension: improvement and maintenance with bosentan. J Heart Lung Transplant 2007; 26:181-187.
Benza R, Park M, Keogh A, Girgis R. Management of pulmonary arterial hypertension with a focus on combination therapies. J Heart Lung Transplant 2007; 26:437-446.
Back to top
